Currently, numerous clinical trials evaluate the efficacy of HER2-targeted CAR T-cells for HER2-positive solid tumors, including NSCLC (NCT02713984, NCT03740256). This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.